Cargando…

Neurotensin is a Versatile Modulator of In Vitro Human Pancreatic Ductal Adenocarcinoma Cell (PDAC) Migration

Background: While the neurotensin (NT) roles in pancreatic cancer growth are well documented, its effects on pancreatic cancer cell migration have not been described. Methods: The NT-induced effects on the migration process of human pancreatic ductal adenocarcinoma cells (PDACs) were characterized b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mijatovic, Tatjana, Gailly, Philippe, Mathieu, Véronique, De Nève, Nancy, Yeaton, Paul, Kiss, Robert, Decaestecker, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2007
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618414/ https://www.ncbi.nlm.nih.gov/pubmed/17641415 http://dx.doi.org/10.1155/2007/701789

Ejemplares similares

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

Neurotensin receptors in pancreatic ductal carcinomas
por: Körner, Meike, et al.
Publicado: (2015)

ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)
por: Sauter, D. R. P., et al.
Publicado: (2014)

Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
por: Chen, Hao, et al.
Publicado: (2023)

MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
por: Prinz, Christian, et al.
Publicado: (2022)

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
por: Kapszewicz, Monika, et al.
Publicado: (2021)

The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment
por: Papadakos, Stavros P., et al.
Publicado: (2023)

Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
por: Felsenstein, Matthäus, et al.
Publicado: (2022)

Screening of potential pain genes in pancreatic ductal adenocarcinoma (PDAC) based on bioinformatics methods
por: Xu, Qian, et al.
Publicado: (2023)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression
por: Almeida, Palloma Porto, et al.
Publicado: (2020)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
por: Freed, Ian M., et al.
Publicado: (2023)

WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4
por: Yin, Wenke, et al.
Publicado: (2023)

MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC)
por: Li, Ce, et al.
Publicado: (2019)

Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes
por: Schlitter, Anna Melissa, et al.
Publicado: (2017)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Gene Expression Characteristics of Tumor and Adjacent Non-Tumor Tissues of Pancreatic Ductal Adenocarcinoma (PDAC) In-Silico
por: Güven, Emine
Publicado: (2022)

Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells
por: Stock, Katharina, et al.
Publicado: (2019)

MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis
por: Lemberger, Moran, et al.
Publicado: (2019)

Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine
por: Frappart, Pierre-Olivier, et al.
Publicado: (2020)

In Silico analyses of host immunity and stroma provide prognostic factors in early stage pancreatic ductal adenocarcinoma (PDAC)
por: Williams, Madison H., et al.
Publicado: (2020)

Expression of Chosen Carcinoembryonic-Related Cell Adhesion Molecules in Pancreatic Intraepithelial Neoplasia (PanIN) Associated with Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma (PDAC)
por: Zińczuk, Justyna, et al.
Publicado: (2019)

A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC)
por: Sun, Yuqi, et al.
Publicado: (2021)

The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis
por: Kumar, Swati, et al.
Publicado: (2022)

Nuclear Position and Shape Deformation of Chromosome 8 Territories in Pancreatic Ductal Adenocarcinoma
por: Timme, Sylvia, et al.
Publicado: (2011)

CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation
por: Wlodarczyk, Barbara, et al.
Publicado: (2023)

Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Tao, Lianyuan, et al.
Publicado: (2016)

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study
por: Zaid, Mohamed, et al.
Publicado: (2020)

Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)
por: Wijnen, Rosa, et al.
Publicado: (2021)

Segmentation of pancreatic ductal adenocarcinoma (PDAC) and surrounding vessels in CT images using deep convolutional neural networks and texture descriptors
por: Mahmoudi, Tahereh, et al.
Publicado: (2022)

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
por: Wang, Xiuchao, et al.
Publicado: (2020)

Deep Convolutional Neural Network-Assisted Feature Extraction for Diagnostic Discrimination and Feature Visualization in Pancreatic Ductal Adenocarcinoma (PDAC) versus Autoimmune Pancreatitis (AIP)
por: Ziegelmayer, Sebastian, et al.
Publicado: (2020)

Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis
por: Li, Xiaoping, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c9525m16vbp5511bdds4hib4pf